226 related articles for article (PubMed ID: 31446247)
1. 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC.
Dokla EME; Fang CS; Abouzid KAM; Chen CS
Eur J Med Chem; 2019 Nov; 182():111607. PubMed ID: 31446247
[TBL] [Abstract][Full Text] [Related]
2. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
El-Sayed NA; Nour MS; Salem MA; Arafa RK
Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker.
Xu C; Han Y; Xu S; Wang R; Yue M; Tian Y; Li X; Zhao Y; Gong P
Eur J Med Chem; 2020 Jan; 186():111867. PubMed ID: 31757525
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors.
Lei H; Fan S; Zhang H; Liu YJ; Hei YY; Zhang JJ; Zheng AQ; Xin M; Zhang SQ
Eur J Med Chem; 2020 Jan; 186():111888. PubMed ID: 31787359
[TBL] [Abstract][Full Text] [Related]
6. Rational design-aided discovery of novel 1,2,4-oxadiazole derivatives as potential EGFR inhibitors.
Unadkat V; Rohit S; Parikh P; Sanna V; Singh S
Bioorg Chem; 2021 Sep; 114():105124. PubMed ID: 34328857
[TBL] [Abstract][Full Text] [Related]
7. 1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities.
Fathi MAA; Abd El-Hafeez AA; Abdelhamid D; Abbas SH; Montano MM; Abdel-Aziz M
Bioorg Chem; 2019 Mar; 84():150-163. PubMed ID: 30502626
[TBL] [Abstract][Full Text] [Related]
8. Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure.
Yamaoka T; Ohba M; Arata S; Ohmori T
J Vis Exp; 2017 Aug; (126):. PubMed ID: 28829429
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 4,6-pyrimidinediamine derivatives as novel dual EGFR/FGFR inhibitors aimed EGFR/FGFR1-positive NSCLC.
Xie Z; Wu K; Wang Y; Pan Y; Chen B; Cheng D; Pan S; Guo T; Du X; Fang L; Wang X; Ye F
Eur J Med Chem; 2020 Feb; 187():111943. PubMed ID: 31846829
[TBL] [Abstract][Full Text] [Related]
10. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR.
Zhang YW; Staal B; Essenburg C; Lewis S; Kaufman D; Vande Woude GF
Mol Cancer Ther; 2013 Aug; 12(8):1429-41. PubMed ID: 23720767
[TBL] [Abstract][Full Text] [Related]
11. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M
Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAF
Al-Wahaibi LH; Gouda AM; Abou-Ghadir OF; Salem OIA; Ali AT; Farghaly HS; Abdelrahman MH; Trembleau L; Abdu-Allah HHM; Youssif BGM
Bioorg Chem; 2020 Nov; 104():104260. PubMed ID: 32920363
[TBL] [Abstract][Full Text] [Related]
13. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
Wu DW; Chen TC; Huang HS; Lee H
Cell Death Dis; 2016 Jun; 7(6):e2290. PubMed ID: 27362807
[TBL] [Abstract][Full Text] [Related]
14. Identification of 2(1H)-pyrimidinones as potential EGFR T790M inhibitors for the treatment of gefitinib-resistant non-small cell lung cancer.
Huang J; Huang J; Wang N; Wang L; Li L; Wang C; Sun X; Li Y; Huang G; Ma X
Bioorg Chem; 2019 Aug; 89():102994. PubMed ID: 31185393
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of antitumor activity of Mobocertinib derivatives, a third-generation EGFR inhibitor.
Fan D; Zhang H; Duan L; Long L; Xu S; Tu Y; Wang L; Zheng P; Zhu W
Bioorg Chem; 2024 Jun; 147():107390. PubMed ID: 38691904
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antitumor evaluation of novel 4-anilino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate derivatives as potential EGFR inhibitors.
Zhang D; Yan Y; Jin G; Liu B; Ma X; Han D; Jia X
Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800110. PubMed ID: 30048007
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.
Wang W; Xu S; Duan Y; Liu X; Li X; Wang C; Zhao B; Zheng P; Zhu W
Eur J Med Chem; 2018 Feb; 145():315-327. PubMed ID: 29331754
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins.
Du Y; Shi S; Shu C; He Y; Xu W; Wu D; Tian Y; Kong M; He J; Xie W; Qiu Y; Xu Y; Zou Y; Zhu Q
Eur J Med Chem; 2024 Jun; 272():116489. PubMed ID: 38759458
[TBL] [Abstract][Full Text] [Related]
19. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
